Cord Blood Program Vision

Cord Blood Program

Our Vision

Dr. Delaney examines cord blood cells she is expanding.

Dr. Delaney examines cord blood cells she is expanding.

Photo by Fred Hutch

Fred Hutch is a world leader in hematopoietic (blood) stem cell transplantation and its use as a treatment for blood cancers, hematological diseases and other conditions. Worldwide, more than a million patients have turned to transplantation to save their lives. For thousands transplantation is not an option because they don't have a genetically matched donor. 

Our work began by pioneering bone marrow transplantation and it continues today in our breakthrough research of cord blood transplantation. Cord blood saves lives, and research in the Delaney Lab is bringing powerful cord blood–based therapies to more people who need a new lifesaving option.

Improving patient options and treatment outcomes

The Hutch’s Cord Blood Program was launched in 2006. Since then, we have performed more than 300 transplants in patients with malignant and non-malignant diseases who range in age from less than 1 year to 71 years.

These clinical trials have focused on improving transplant outcomes and also overcoming cord blood’s greatest hurdle — the small number of cells in each cord blood unit.

A vision for worldwide availability

Dr. Colleen Delaney, Director for the Fred Hutch Cord Blood Program, developed a method for multiplying, or expanding, key stem cells in cord blood, with the goal of extending the use of this expanded cord blood product into something that could be ordered up by doctors at a moment’s notice.  Her vision is to create a therapy that can become FDA approved and be given to patients around the world.


Stories of inspiration and hope

Every patient, care-giver or family has a compelling story to tell about the journey they went through to get a cord blood transplant and the special care they received. We invite you to read our patient, family and caregiver stories, and we encourage you to share your story.